TR1801-ADC in Patients With Tumors That Express c-Met

Summary

First-in-human, Phase 1 study to assess safety, tolerability, and pharmacokinetics of TR1801-ADC in patients with select solid tumors that express c-Met.

Timeline

Start

2019-08-14

Primary completion

2023-07-04

Completion

2023-12-31

Outcome

Outcome not reported

Stopped (Business): “Financial funds were withdrawn by investors and study was stopped”

Drugs

Indications